Mural Oncology plc (NASDAQ: MURA)
$3.45
+0.1400 ( +4.23% ) 289.3K
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
Market Data
Open
$3.45
Previous close
$3.31
Volume
289.3K
Market cap
$58.39M
Day range
$3.28 - $3.57
52 week range
$2.88 - $17.00
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 13 | May 14, 2024 |
10-q | Quarterly Reports | 65 | May 14, 2024 |
def | Proxies and info statements | 5 | Apr 12, 2024 |
ars | Annual reports | 1 | Apr 12, 2024 |
4/a | Other | 1 | Apr 11, 2024 |
8-k | 8K-related | 14 | Mar 26, 2024 |
10-k | Annual reports | 98 | Mar 26, 2024 |
4 | Insider transactions | 1 | Mar 04, 2024 |
4 | Insider transactions | 1 | Mar 04, 2024 |
8-k | 8K-related | 40 | Jan 08, 2024 |